Cover Image
市場調查報告書

憂鬱症:開發中產品分析

Depression - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213106
出版日期 內容資訊 英文 476 Pages
訂單完成後即時交付
價格
Back to Top
憂鬱症:開發中產品分析 Depression - Pipeline Review, H1 2017
出版日期: 2017年04月11日 內容資訊: 英文 476 Pages
簡介

憂鬱症會引起心理障礙,持續性的悲傷和興趣喪失。一般常見的名稱有重度憂鬱症、重度憂鬱性障礙或是臨床憂鬱症。常見有睡眠障礙(失眠症,過眠症),食慾的變化,神經不安症,興奮或無法沉靜,身體問題(背部痛,頭痛)的徵兆和症狀。治療法包含抗憂鬱藥,心情穩定劑或抗精神病藥等。

本報告提供憂鬱症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

憂鬱症概要

治療藥的開發

憂鬱症:企業開發中的治療藥

憂鬱症:大學/機關研究中的治療藥

憂鬱症:開發中產品概況

憂鬱症:企業開發中的產品

憂鬱症:大學/機關研究中的產品

憂鬱症的治療藥的開發企業

憂鬱症:治療藥的評估

藥物簡介

憂鬱症:最近的開發平台趨勢

憂鬱症:暫停中的計劃

憂鬱症:開發中止的產品

憂鬱症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9171IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2017, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 14, 27, 23, 74, 15 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 17 and 8 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Depression - Overview
  • Depression - Therapeutics Development
  • Depression - Therapeutics Assessment
  • Depression - Companies Involved in Therapeutics Development
  • Depression - Drug Profiles
  • Depression - Dormant Projects
  • Depression - Discontinued Products
  • Depression - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Depression, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Depression - Pipeline by 4D Pharma PLC, H1 2017
  • Depression - Pipeline by AB Science SA, H1 2017
  • Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Adamed Sp z oo, H1 2017
  • Depression - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Alkermes Plc, H1 2017
  • Depression - Pipeline by Allergan Plc, H1 2017
  • Depression - Pipeline by Alvogen Korea Co Ltd, H1 2017
  • Depression - Pipeline by Amorsa Therapeutics Inc, H1 2017
  • Depression - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Depression - Pipeline by Angelini Group, H1 2017
  • Depression - Pipeline by Angita BV, H1 2017
  • Depression - Pipeline by Araim Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by AstraZeneca Plc, H1 2017
  • Depression - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Axsome Therapeutics Inc, H1 2017
  • Depression - Pipeline by Azevan Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by BioCrea GmbH, H1 2017
  • Depression - Pipeline by BioLite Inc, H1 2017
  • Depression - Pipeline by Bionomics Ltd, H1 2017
  • Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Depression - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Depression - Pipeline by Calico LLC, H1 2017
  • Depression - Pipeline by Celgene Corp, H1 2017
  • Depression - Pipeline by Celon Pharma SA, H1 2017
  • Depression - Pipeline by Cerecor Inc, H1 2017
  • Depression - Pipeline by Clera Inc, H1 2017
  • Depression - Pipeline by Delpor Inc, H1 2017
  • Depression - Pipeline by Domain Therapeutics SA, H1 2017
  • Depression - Pipeline by Eisai Co Ltd, H1 2017
  • Depression - Pipeline by Eli Lilly and Company, H1 2017
  • Depression - Pipeline by Evotec AG, H1 2017
  • Depression - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Depression - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by FPRT Bio Inc, H1 2017
  • Depression - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Depression - Pipeline by GliaCure Inc, H1 2017
  • Depression - Pipeline by H. Lundbeck A/S, H1 2017
  • Depression - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Depression - Pipeline by Hua Medicine (Shanghai) Ltd, H1 2017
  • Depression - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Depression - Pipeline by Impel NeuroPharma Inc, H1 2017
  • Depression - Pipeline by INSYS Therapeutics Inc, H1 2017
  • Depression - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
  • Depression - Pipeline by Intra-Cellular Therapies Inc, H1 2017
  • Depression - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Johnson & Johnson, H1 2017
  • Depression - Pipeline by KemPharm Inc, H1 2017
  • Depression - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Depression - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Depression - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Depression - Pipeline by Luye Pharma Group Ltd, H1 2017
  • Depression - Pipeline by Mapi Pharma Ltd, H1 2017
  • Depression - Pipeline by Mapreg SAS, H1 2017
  • Depression - Pipeline by Medlab Clinical Ltd, H1 2017
  • Depression - Pipeline by Meta-IQ ApS, H1 2017
  • Depression - Pipeline by Methylation Sciences Inc, H1 2017
  • Depression - Pipeline by miCure Therapeutics Ltd, H1 2017
  • Depression - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Depression - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
  • Depression - Pipeline by Neuralstem Inc, H1 2017
  • Depression - Pipeline by Neurocrine Biosciences Inc, H1 2017
  • Depression - Pipeline by NeuroNascent Inc, H1 2017
  • Depression - Pipeline by NeurOp Inc, H1 2017
  • Depression - Pipeline by Newron Pharmaceuticals SpA, H1 2017
  • Depression - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
  • Depression - Pipeline by nLife Therapeutics SL, H1 2017
  • Depression - Pipeline by Omeros Corp, H1 2017
  • Depression - Pipeline by Orexigen Therapeutics Inc, H1 2017
  • Depression - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Depression - Pipeline by Pfizer Inc, H1 2017
  • Depression - Pipeline by Pherin Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Polleo Pharma Ltd, H1 2017
  • Depression - Pipeline by Protagenic Therapeutics Inc, H1 2017
  • Depression - Pipeline by Relmada Therapeutics Inc, H1 2017
  • Depression - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Richter Gedeon Nyrt, H1 2017
  • Depression - Pipeline by Sage Therapeutics Inc, H1 2017
  • Depression - Pipeline by Saniona AB, H1 2017
  • Depression - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Depression - Pipeline by Sound Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Depression - Pipeline by Supernus Pharmaceuticals Inc, H1 2017
  • Depression - Pipeline by Suven Life Sciences Ltd, H1 2017
  • Depression - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
  • Depression - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Depression - Pipeline by Tetra Discovery Partners LLC, H1 2017
  • Depression - Pipeline by Trevena Inc, H1 2017
  • Depression - Pipeline by TRImaran Pharma Inc, H1 2017
  • Depression - Pipeline by VistaGen Therapeutics Inc, H1 2017
  • Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd, H1 2017
  • Depression - Pipeline by Zogenix Inc, H1 2017
  • Depression - Pipeline by Zysis Ltd, H1 2017
  • Depression - Dormant Projects, H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Depression - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Depression - Discontinued Products, H1 2017
  • Depression - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Depression - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Depression - Discontinued Products, H1 2017 (Contd..3), H1 2017
  • Depression - Discontinued Products, H1 2017 (Contd..4), H1 2017

List of Figures

  • Number of Products under Development for Depression, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top